RU2314307C2 - СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ - Google Patents

СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ Download PDF

Info

Publication number
RU2314307C2
RU2314307C2 RU2003126258/04A RU2003126258A RU2314307C2 RU 2314307 C2 RU2314307 C2 RU 2314307C2 RU 2003126258/04 A RU2003126258/04 A RU 2003126258/04A RU 2003126258 A RU2003126258 A RU 2003126258A RU 2314307 C2 RU2314307 C2 RU 2314307C2
Authority
RU
Russia
Prior art keywords
compound
animal body
imidazo
methylpropyl
amine
Prior art date
Application number
RU2003126258/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003126258A (ru
Inventor
Кайл Дж. ЛИНГСТРОМ (US)
Кайл Дж. ЛИНГСТРОМ
Джон Ф. ГЕРСТЕР (US)
Джон Ф. Герстер
Original Assignee
Миннесота Майнинг Энд Мэнюфекчуринг Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Миннесота Майнинг Энд Мэнюфекчуринг Компани filed Critical Миннесота Майнинг Энд Мэнюфекчуринг Компани
Publication of RU2003126258A publication Critical patent/RU2003126258A/ru
Application granted granted Critical
Publication of RU2314307C2 publication Critical patent/RU2314307C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2003126258/04A 1997-12-11 1998-12-11 СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ RU2314307C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6927697P 1997-12-11 1997-12-11
US60/069.276 1997-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2000114496/04A Division RU2221798C2 (ru) 1997-12-11 1998-12-11 Имидазонафтиридины, фармацевтическая композиция на их основе, способ стимуляции биосинтеза цитокина и промежуточные вещества

Publications (2)

Publication Number Publication Date
RU2003126258A RU2003126258A (ru) 2005-03-10
RU2314307C2 true RU2314307C2 (ru) 2008-01-10

Family

ID=22087889

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2003126258/04A RU2314307C2 (ru) 1997-12-11 1998-12-11 СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ
RU2000114496/04A RU2221798C2 (ru) 1997-12-11 1998-12-11 Имидазонафтиридины, фармацевтическая композиция на их основе, способ стимуляции биосинтеза цитокина и промежуточные вещества
RU2003126259/04A RU2312867C2 (ru) 1997-12-11 1998-12-11 СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-с][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2000114496/04A RU2221798C2 (ru) 1997-12-11 1998-12-11 Имидазонафтиридины, фармацевтическая композиция на их основе, способ стимуляции биосинтеза цитокина и промежуточные вещества
RU2003126259/04A RU2312867C2 (ru) 1997-12-11 1998-12-11 СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-с][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ

Country Status (28)

Country Link
US (14) US6194425B1 (US06894165-20050517-C00064.png)
EP (1) EP1040112B1 (US06894165-20050517-C00064.png)
JP (4) JP4283438B2 (US06894165-20050517-C00064.png)
KR (3) KR100563175B1 (US06894165-20050517-C00064.png)
CN (1) CN1154647C (US06894165-20050517-C00064.png)
AT (3) ATE333456T1 (US06894165-20050517-C00064.png)
AU (1) AU753864B2 (US06894165-20050517-C00064.png)
BR (1) BR9814275A (US06894165-20050517-C00064.png)
CA (1) CA2311456C (US06894165-20050517-C00064.png)
CZ (1) CZ307184B6 (US06894165-20050517-C00064.png)
DE (3) DE69835844T2 (US06894165-20050517-C00064.png)
DK (1) DK1512686T3 (US06894165-20050517-C00064.png)
EE (1) EE04314B1 (US06894165-20050517-C00064.png)
ES (3) ES2270249T3 (US06894165-20050517-C00064.png)
HK (1) HK1070655A1 (US06894165-20050517-C00064.png)
HR (1) HRP20000363B1 (US06894165-20050517-C00064.png)
HU (1) HUP0101155A3 (US06894165-20050517-C00064.png)
IL (4) IL136556A0 (US06894165-20050517-C00064.png)
NO (3) NO316687B1 (US06894165-20050517-C00064.png)
NZ (1) NZ504776A (US06894165-20050517-C00064.png)
PL (1) PL193915B1 (US06894165-20050517-C00064.png)
PT (3) PT1512685E (US06894165-20050517-C00064.png)
RU (3) RU2314307C2 (US06894165-20050517-C00064.png)
SI (1) SI1512686T1 (US06894165-20050517-C00064.png)
SK (2) SK285872B6 (US06894165-20050517-C00064.png)
TR (1) TR200001705T2 (US06894165-20050517-C00064.png)
UA (1) UA67760C2 (US06894165-20050517-C00064.png)
WO (1) WO1999029693A1 (US06894165-20050517-C00064.png)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
EP1140091B1 (en) 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
SI1198233T1 (sl) * 1999-06-10 2007-02-28 3M Innovative Properties Co S sulfonamidom in sulfamidom substituirani imidazokinolini
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
EP1438958A1 (en) * 1999-06-10 2004-07-21 3M Innovative Properties Company Carbamate substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20040209877A1 (en) * 2000-04-13 2004-10-21 Shelby Nancy J. Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
AU2006216669A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
AU3249802A (en) * 2000-12-08 2002-06-18 3M Innovative Properties Co Screening method for identifying compounds that selectively induce interferon alpha
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
CA2467828C (en) * 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1478327T1 (sl) * 2002-02-22 2015-08-31 Meda Ab Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B
AU2003237386A1 (en) 2002-06-07 2003-12-22 3M Innovative Properties Company Ether substituted imidazopyridines
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6818650B2 (en) * 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
CA2517655A1 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
US8426457B2 (en) * 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2005012488A2 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Compositions for encapsulation and controlled release
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
WO2005018556A2 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
AU2004266657B2 (en) 2003-08-14 2009-07-02 3M Innovative Properties Company Lipid-modified immune response modifiers
JP4913593B2 (ja) * 2003-08-14 2012-04-11 スリーエム イノベイティブ プロパティズ カンパニー 脂質修飾された免疫応答調整剤
CA2551075A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co METHODS RELATING TO THE TREATMENT OF GIANCES
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
CA2536530A1 (en) 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1h-imidazo(4,5-c)quinolines and acid addition salts thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1680080A4 (en) * 2003-10-31 2007-10-31 3M Innovative Properties Co NEUTROPHILIC ACTIVATION THROUGH COMPOUNDS TO MODIFY THE IMMUNE RESPONSE
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
EP1686992A4 (en) * 2003-11-25 2009-11-04 3M Innovative Properties Co HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
AR048289A1 (es) * 2003-12-04 2006-04-19 3M Innovative Properties Co Eteres de anillos imidazo sulfona sustituidos.
JP2007517035A (ja) * 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
WO2005066172A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
CA2551399A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
ES2665342T3 (es) 2004-03-15 2018-04-25 Meda Ab Formulaciones y métodos para modificadores de la respuesta inmune
CA2559863A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
AU2005244260B2 (en) * 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
CN101426524A (zh) * 2004-04-28 2009-05-06 3M创新有限公司 用于粘膜接种疫苗的组合物和方法
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP5128940B2 (ja) * 2004-06-18 2013-01-23 スリーエム イノベイティブ プロパティズ カンパニー 置換イミダゾキノリン、イミダゾピリジン、およびイミダゾナフチリジン
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co HIV IMMUNOSTIMATORY COMPOSITIONS
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
WO2006029115A2 (en) * 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
JP5209312B2 (ja) * 2004-09-02 2013-06-12 スリーエム イノベイティブ プロパティズ カンパニー １−アルコキシ１ｈ−イミダゾ環系および方法
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
WO2006053166A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
ATE538124T1 (de) 2004-11-12 2012-01-15 Bristol Myers Squibb Co Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
AU2005321912B2 (en) 2004-12-30 2012-04-05 3M Innovative Properties Company Treatment for cutaneous metastases
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2005322898B2 (en) * 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
AR052447A1 (es) * 2004-12-30 2007-03-21 3M Innovative Properties Co Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
EA200701584A1 (ru) 2005-01-27 2008-02-28 Альма Матер Студиорум - Университа' Ди Болонья Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
US20080318998A1 (en) * 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US8658666B2 (en) * 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2598639A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
JP2008538203A (ja) * 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
AU2006216798A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1851224A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
CA2602098A1 (en) * 2005-03-14 2006-09-21 Graceway Pharmaceuticals, Llc Method of treating actinic keratosis
AU2006244635A1 (en) * 2005-04-01 2006-11-16 Coley Pharmaceutical Group, Inc. Ring closing and related methods and intermediates
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
US20080234318A1 (en) * 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
JP2009507856A (ja) * 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｎ−｛２−［４−アミノ−２−（エトキシメチル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］−１，１−ジメチルエチル｝メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
JP5247458B2 (ja) * 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
WO2007079086A1 (en) * 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
US8951528B2 (en) * 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
WO2007143526A2 (en) * 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008010963A2 (en) * 2006-07-18 2008-01-24 3M Innovative Properties Company Immune response modifier formulations
WO2008016475A2 (en) * 2006-07-31 2008-02-07 3M Innovative Properties Company Immune response modifier compositions and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
JP2010514679A (ja) * 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
WO2008098232A1 (en) * 2007-02-08 2008-08-14 Graceway Pharmaceuticals, Llc Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
EP2378876B1 (en) 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
EP2411521B1 (en) 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US8349827B2 (en) * 2009-03-31 2013-01-08 Arqule, Inc. Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
US8511006B2 (en) * 2009-07-02 2013-08-20 Owens Corning Intellectual Capital, Llc Building-integrated solar-panel roof element systems
AU2010274097B2 (en) 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
TW201129565A (en) * 2010-01-12 2011-09-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011163617A1 (en) 2010-06-25 2011-12-29 Graceway Pharmaceuticals, Llc Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Formulations and formulations for lipidized immune response modifying compounds and related processes
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013040447A2 (en) 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
ES2727481T3 (es) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
US10076535B2 (en) 2012-04-27 2018-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing
MX359257B (es) 2012-05-04 2018-09-19 Pfizer Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
HUE051988T2 (hu) 2013-01-07 2021-04-28 Univ Pennsylvania Készítmények és eljárások bõr T-sejt lymphoma kezelésére
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
EP3065741B1 (en) 2013-11-05 2021-09-22 3M Innovative Properties Company Sesame oil based injection formulations
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP4001311A1 (en) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US11680244B2 (en) 2015-05-20 2023-06-20 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
US10118925B2 (en) 2015-08-31 2018-11-06 3M Innovative Properties Company Imidazo[4,5-c] ring compounds containing substituted guanidine groups
AU2016317637B2 (en) 2015-08-31 2019-01-31 Solventum Intellectual Properties Company Guanidine substituted imidazo[4,5-c] ring compounds
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
JP6883806B2 (ja) * 2016-03-09 2021-06-09 国立大学法人大阪大学 化合物、及びこれを含む有機半導体材料
CN109562057A (zh) 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
EP3504215B1 (en) 2016-08-26 2022-04-06 3M Innovative Properties Company Fused [1,2]imidazo[4,5-c]ring compounds substituted with guanidino groups
CA3033542A1 (en) 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity
IL266562B1 (en) 2016-11-09 2024-07-01 Univ Texas Pharmaceutical compositions for immune regulation adapted for use in the patient sensitive to allergen-induced asthma
US11426566B2 (en) 2016-12-14 2022-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TLR modulator
AU2017378398B2 (en) 2016-12-14 2023-02-02 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
CA3045475A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
CA3045472A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018160552A1 (en) 2017-03-01 2018-09-07 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
JP7080501B2 (ja) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
JP2021503005A (ja) 2017-11-14 2021-02-04 ダイナバックス テクノロジーズ コーポレイション Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物
JP7251893B2 (ja) 2018-02-28 2023-04-04 スリーエム イノベイティブ プロパティズ カンパニー Ｎ－１分枝基を有する置換イミダゾ［４，５－ｃ］キノリン化合物
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
SG11202010580TA (en) 2018-05-23 2020-12-30 Pfizer Antibodies specific for cd3 and uses thereof
KR102584675B1 (ko) 2018-05-23 2023-10-05 화이자 인코포레이티드 GUCY2c에 특이적인 항체 및 이의 용도
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
CN113166143B (zh) 2018-11-26 2024-06-04 舒万诺知识产权公司 N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US20220177471A1 (en) 2019-06-06 2022-06-09 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
EP3983408A1 (en) 2019-06-12 2022-04-20 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
WO2021124073A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
KR20230022246A (ko) 2020-07-17 2023-02-14 화이자 인코포레이티드 치료 항체 및 그의 용도

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3764681A (en) * 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ES2071340T3 (es) 1990-10-05 1995-06-16 Minnesota Mining & Mfg Procedimiento para la preparacion de imidazo(4,5-c)quinolin-4-aminas.
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE69737935T2 (de) 1996-10-25 2008-04-03 Minnesota Mining And Manufacturing Co., St. Paul Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
PT839810E (pt) * 1996-11-04 2003-01-31 Bayer Cropscience Sa 1-poliarilpirazois como pesticidas
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
JPH11255926A (ja) 1998-03-13 1999-09-21 Toray Ind Inc シリコーン成型品およびその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
EP1140091B1 (en) 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
US6545485B1 (en) * 1999-01-21 2003-04-08 Radar Engineers Ultrasonic pinpointer for power system sources of interference
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
AU3249802A (en) * 2000-12-08 2002-06-18 3M Innovative Properties Co Screening method for identifying compounds that selectively induce interferon alpha
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
CA2449754A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
WO2003020889A2 (en) 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US6667347B2 (en) * 2001-09-14 2003-12-23 Chevron U.S.A. Inc. Scrubbing CO2 from methane-containing gases using an aqueous stream
WO2003094836A2 (en) * 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
CA2467828C (en) * 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1478327T1 (sl) * 2002-02-22 2015-08-31 Meda Ab Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003101949A2 (en) * 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AU2003237386A1 (en) * 2002-06-07 2003-12-22 3M Innovative Properties Company Ether substituted imidazopyridines
WO2004032829A2 (en) * 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6818650B2 (en) * 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
EP1572236A4 (en) * 2002-11-14 2007-01-03 Pintex Pharmaceuticals Inc PINE RATE1 IN HEALTHY FABRIC AND IN CANCER FABRIC
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
EP1590348A1 (en) * 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
AU2004218349A1 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
CA2517655A1 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
US8426457B2 (en) * 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
AU2004220465A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
OA13310A (en) * 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
AR052447A1 (es) * 2004-12-30 2007-03-21 3M Innovative Properties Co Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina

Also Published As

Publication number Publication date
ES2270249T3 (es) 2007-04-01
US6747040B2 (en) 2004-06-08
WO1999029693A1 (en) 1999-06-17
US20030083500A1 (en) 2003-05-01
RU2003126259A (ru) 2005-02-27
JP2008115190A (ja) 2008-05-22
US20050288320A1 (en) 2005-12-29
EP1040112A1 (en) 2000-10-04
RU2003126258A (ru) 2005-03-10
HUP0101155A3 (en) 2002-10-28
IL136556A (en) 2007-03-08
DK1512686T3 (da) 2007-01-15
PT1040112E (pt) 2005-01-31
DE69826518T2 (de) 2005-09-22
UA67760C2 (uk) 2004-07-15
KR20010033016A (ko) 2001-04-25
HK1070655A1 (en) 2005-06-24
US20020173654A1 (en) 2002-11-21
SK8352000A3 (en) 2001-03-12
US7335773B2 (en) 2008-02-26
EP1040112B1 (en) 2004-09-22
US20030096998A1 (en) 2003-05-22
NO316687B1 (no) 2004-04-05
HUP0101155A2 (hu) 2001-12-28
US6699878B2 (en) 2004-03-02
RU2312867C2 (ru) 2007-12-20
US20070167481A1 (en) 2007-07-19
PL341159A1 (en) 2001-03-26
KR100642702B1 (ko) 2006-11-10
IL178091A (en) 2007-10-31
CN1154647C (zh) 2004-06-23
US6894165B2 (en) 2005-05-17
HRP20000363B1 (en) 2005-06-30
US6797716B2 (en) 2004-09-28
AU1912399A (en) 1999-06-28
US6624172B2 (en) 2003-09-23
EE200000349A (et) 2001-10-15
PT1512685E (pt) 2006-12-29
US6638944B2 (en) 2003-10-28
NO20002663L (no) 2000-08-11
CN1284957A (zh) 2001-02-21
NO20035718D0 (no) 2003-12-19
AU753864B2 (en) 2002-10-31
DE69835844T2 (de) 2007-04-19
ES2273138T3 (es) 2007-05-01
US6194425B1 (en) 2001-02-27
KR100563175B1 (ko) 2006-03-27
RU2221798C2 (ru) 2004-01-20
NO20002663D0 (no) 2000-05-24
US20060128674A1 (en) 2006-06-15
NO20035718L (no) 2000-08-11
BR9814275A (pt) 2000-10-03
JP2006083188A (ja) 2006-03-30
KR20040011532A (ko) 2004-02-05
TR200001705T2 (tr) 2001-07-23
ATE338757T1 (de) 2006-09-15
JP2001525411A (ja) 2001-12-11
US6693113B2 (en) 2004-02-17
DE69835844D1 (de) 2006-10-19
DE69826518D1 (de) 2004-10-28
US20040204436A1 (en) 2004-10-14
KR20040011533A (ko) 2004-02-05
CZ307184B6 (cs) 2018-02-28
PL193915B1 (pl) 2007-03-30
US20080091010A1 (en) 2008-04-17
US7038051B2 (en) 2006-05-02
ES2227902T3 (es) 2005-04-01
US20030212093A1 (en) 2003-11-13
SI1512686T1 (sl) 2007-02-28
IL136556A0 (en) 2001-06-14
CZ2007268A3 (cs) 2016-09-29
US7678918B2 (en) 2010-03-16
PT1512686E (pt) 2007-01-31
CA2311456C (en) 2010-11-02
ATE277046T1 (de) 2004-10-15
JP4203067B2 (ja) 2008-12-24
US20040023932A1 (en) 2004-02-05
US6514985B1 (en) 2003-02-04
CA2311456A1 (en) 1999-06-17
SK285872B6 (sk) 2007-10-04
JP4283438B2 (ja) 2009-06-24
DE69835309T2 (de) 2007-07-19
NO328045B1 (no) 2009-11-16
NZ504776A (en) 2002-07-26
DE69835309D1 (de) 2006-08-31
WO1999029693A8 (en) 2004-11-04
US6949646B2 (en) 2005-09-27
HRP20000363A2 (en) 2001-06-30
IL178092A (en) 2007-10-31
EE04314B1 (et) 2004-06-15
ATE333456T1 (de) 2006-08-15
KR100642703B1 (ko) 2006-11-10
US20040006098A1 (en) 2004-01-08
JP2007262093A (ja) 2007-10-11
SK286304B6 (en) 2008-07-07
NO20035719D0 (no) 2003-12-19
US20050107421A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
RU2314307C2 (ru) СОЕДИНЕНИЕ, ВКЛЮЧАЮЩЕЕ 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c][1,5]НАФТИРИДИН-4-АМИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБ СТИМУЛЯЦИИ БИОСИНТЕЗА ЦИТОКИНА В ОРГАНИЗМЕ ЖИВОТНЫХ
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
DK326885D0 (da) Fluorescerende mono-, di- eller polyamider og fremgangsmaade til fremstilling heraf
RU2005138915A (ru) Сульфонамид замещенные имидазохинолины
EP1862458A3 (en) Therapeutic agents useful for treating pain
EP2044938A3 (en) Radioprotectors
MX9203744A (es) Analogos de camptotecina solubles en agua utiles para inhibir el crecimiento de celulas de tumor de animal.
BG94837A (bg) О-метилни производни на азитромицин а, метод за тяхното получаване и приложението им като фармацевтични препарати
UA19808A (uk) Спосіб одержаhhя феhілалкіламіhів або солей цих сполук
RU94017851A (ru) Ингибиторы протеолитических ферментов на основе производных сахарина, фармацевтическая композиция для лечения дегеративных заболеваний
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
HK1056557A1 (en) Transesterification process for preparation of synthetic chlorophyll and bacteriochlorophyll derivative
IT8622160A0 (it) Procedimento per la preparazione di alimenti di origine animale.
BG49827A3 (en) Method for preparing a clean byologic active recombinative human colonium stimulating factor
ATE123381T1 (de) Verabreichung von wirkstoffen zu wassertieren mittels überschallen.
EP1997818A3 (en) Quinolinone derivatives and their use to treat pain
EP1609856A3 (en) Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
EP0327709A3 (en) Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use
AU613583B2 (en) Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
EA199900755A1 (ru) Производное хинолин-2-карбоновой кислоты и его применение в качестве антагониста возбуждающих аминокислот
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
RU93005182A (ru) Производные октагидронафталиноксима, фармацевтическая композиция, способ лечения, способ их получения, способы получения исходных материалов и культуры микроорганизмов
EP0209843A3 (en) Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 1-2008 FOR TAG: (73)